Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 1/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.54 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11704162 | 0.94 | CHRNB4 (0.54) | CHRNB4CHRNA3NOS1PDPK1HTR2C | |
| SCHEMBL11701290 | 0.92 | CHRNB4 (0.52) | CHRNB4CHRNA3NOS1HTR2C | |
| SCHEMBL11704954 | 0.92 | CHRNB4 (0.52) | CHRNB4CHRNA3NOS1HTR2C | |
| SCHEMBL221689 | 0.88 | CHRNB4 (0.59) | CHRNB4CHRNA3PDPK1HTR2CCHRNB2 | |
| SCHEMBL30166929 | 0.88 | CHRNB4 (0.59) | CHRNB4CHRNA3PDPK1HTR2CCHRNB2 | |
| SCHEMBL23797352 | 0.88 | CHRNB4 (0.59) | CHRNB4CHRNA3PDPK1HTR2CCHRNB2 | |
| SCHEMBL2913620 | 0.86 | CHRNB4 (0.44) | CHRNB4CHRNA3NOS3NOS1NOS2 | |
| SCHEMBL16099720 | 0.85 | CHRNB4 (0.46) | CHRNB4CHRNA3NOS3NOS1NOS2 | |
| SCHEMBL779938 | 0.82 | CHRNB4 (0.46) | CHRNB4CHRNA3HTR2C | |
| SCHEMBL42781 | 0.80 | PTGDR2 (0.48) | CHRNB4CHRNA3NOS1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285407-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2023-09-14 | — | — | US | disclosed |
| US-11717524-B1 | Varenicline compound and process of manufacture thereof | PAR PHARMACEUTICAL, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| EP-2222647-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | Cephalon, Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| WO-2008051547-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| US-4049701-A | ANALGESICS, ANTIINFLAMMATORY | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-09-20 | — | — | US | disclosed |
| US-4001326-A | ANALGESICS, ANTIINFLAMMATORY AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-01-04 | — | — | US | disclosed |
| US-4001331-A | ANTIINFLAMMATORY, ANALGESIC | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-01-04 | — | — | US | disclosed |
| US-3979434-A | ANALGESICS, ANTIINFLAMMATORY | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-09-07 | — | — | US | disclosed |
| US-3976696-A | ANALGESIC, ANTIINFLAMMATORY | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-08-24 | — | — | US | disclosed |
| US-3976693-A | ANALGESIC, ANTIINFLAMMATORY | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-08-24 | — | — | US | disclosed |
| US-3957872-A | ANALGESICS, ANTIINFLAMMATORY AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-05-18 | — | — | US | disclosed |
| US-3937736-A | ANALGESICS, ANTIINFLAMMATORY AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-02-10 | — | — | US | disclosed |
| US-3931328-A | CARBURETOR | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285407-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | COMT, CYP2C9, CYP3A7 | CHRNB4 101/4885CHRNA3 70/4885NOS3 1118/4885 |
| US-11717524-B1 | Varenicline compound and process of manufacture thereof | COMT, CYP2C9, CYP3A7 | CHRNB4 43/4885CHRNA3 61/4885NOS3 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.